An in silico disease model for the development of FXR agonist EYP001 as a therapy for HBV infection.


(2019), AASLD - The Liver Meeting, Boston (USA)

Claudio Monteiro, Lara Bruezière, Samuel Laheux, Marc Hommel, Pauline Radreau, Elise Roy, Raphaël Darteil, Patrice André, Jean-Pierre Boissel, Jacky Vonderscher and Pietro Scalfaro.

A regulatory landscape shift for in silico clinical trials


(2019) Regulatory Rapporteur, vol. 16, no. 11, pp. 18-21

Cécile F Rousseau, Cécile Crozatier, David A duVerle, Marc Buyse, Susan E Carter, Emmanuelle M Voisin, François-Henri Boissel

From Clinical Trial Efficacy to Real-Life Effectiveness: Why Conventional Metrics do not Work.


(2019) Drugs-real world outcomes, vol. 6, no. 3, pp. 125-132

Jean-Pierre Boissel, Frédéric Cogny, Marko Nicholas, François-Henri Boissel.

In silico exploration of immunotherapeutics combinations in lymphoma


(2018), ICSB, Lyon (France)

Lara Brueziere, Adèle L’Hostis, Eulalie Landèche, Emmanuelle Bechet, Polina Kurbatova, Loïc Etheve, Jean-Pierre Boissel.

A logical modelling approach to prepare and accelerate the design of ODE models: Application to bile acid metabolism


(2018), ICSB, Lyon (France)

Lara Brueziere, Eliott Tixier, Elise Roy, Arnaud Poret, Claudio Monteiro, Pietro Scalfaro, Jean-Pierre Boissel.

An in silico HBV model predicts viral response to the oral non-steroidal carboxylic acid FXR agonist EYP001a.


(2018), PAGE meeting, Montreux (Switzerland)

Claudio Monteiro, Evgueni Jacob, Bastien Martin, Samuel Laheux, Diane Sampson, Elise Roy, Jacky Vonderscher, Pietro Scalfaro, Patrice André, Jean-Pierre Boissel.

Comparative transcriptomic analysis between an artificially induced SIRS in healthy individuals and spontaneous sepsis


(2015) Comptes Rendus Biologies, vol. 338, no. 10, pp. 635-642

Claudio Monteiro, Jean-Pierre Boissel, François Gueyffier, Gustavo Olivera-Botello

Bridging Systems Medicine and Patient Needs


(2015) CPT: Pharmacometrics & Systems Pharmacology, vol. 4, no. 3, pp. 135-145

J-P Boissel, C Auffray, D Noble, L Hood, F-H Boissel

Comparison of an effect-model-law-based method versus traditional clinical practice guidelines for optimal treatment decision-making: application to statin treatment in the French population


(2014) Journal of The Royal Society Interface , vol. 11, no. 100, pp. 20140867-20140867

R. Kahoul, F. Gueyffier, E. Amsallem, M. Haugh, I. Marchant, F.-H. Boissel, J.-P. Boissel

Prediction of chronic lung allograft dysfunction: a systems medicine challenge


(2014) European Respiratory Journal, vol. 43, no. 3, pp. 689-693

C. Pison, A. Magnan, K. Botturi, M. Seve, S. Brouard, B. J. Marsland, F. Ernst, T. Paprotka, K. Deplanche, A. Fritz, V. Siroux, J.-P. Boissel, P. A. Corris, C. Auffray, L. P. Nicod, on behalf of the SysCLAD consortium

Effect Model Law: An Approach for the Implementation of Personalized Medicine


(2013) Journal of Personalized Medicine , vol. 3, no. 3, pp. 177-190

Jean-Pierre Boissel, Riad Kahoul, Draltan Marin, François-Henri Boissel

Towards personalized medicine: exploring the consequences of the effect model-based approach


(2011) Personalized Medicine, vol. 8, no. 5, pp. 581-586

Jean-Pierre Boissel, Riad Kahoul, Emmanuel Amsallem, François Gueyffier, Margaret Haugh, François-Henri Boissel